**4. Artificial intelligence (AI) use in T1D research**

Although various T1D prevention trials have been conducted, response to preventative therapies appears to be limited to only a few individuals. A major factor in this lack of response is the difficulty identifying appropriate high-risk subjects who would benefit from such trials. Personalized prevention strategies based on one's own risk and etiology may prove to be more efficient than prevention for the whole at-risk population. Therefore, a panel of multiple biomarkers is needed to identify individual risks for potential subjects in T1D prevention trials.


*ELISA: enzyme-linked immunosorbent assay, Array Bead: Luminex bead array, NAPPA: Nucleic Acid Programmable Protein Arrays.*
